A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 May 2015
At a glance
- Drugs TAS 266 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 01 Oct 2012 Planned End Date changed from 1 Feb 2014 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.